Get the Stockscreener App
1.05
5.54%
0.0551
Pre-market:
1.05
Cardiol Therapeutics Inc stock is traded at $1.05, with a volume of 1.42M.
It is up +5.54% in the last 24 hours and up +4.48% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$0.9949
Open:
$0.99
24h Volume:
1.42M
Relative Volume:
3.84
Market Cap:
$117.26M
Revenue:
-
Net Income/Loss:
$-24.89M
P/E Ratio:
-3.5023
EPS:
-0.2998
Net Cash Flow:
$-17.20M
1W Performance:
+0.00%
1M Performance:
+4.48%
6M Performance:
-3.67%
1Y Performance:
-6.25%
1-Day Range:
$0.9718
$1.08
1-Week Range:
$0.8974
$1.08
52-Week Range:
$0.7709
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.05 | 117.26M | 0 | -24.89M | -17.20M | -0.2998 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Cardiol Therapeutics (TSX:CRDL) Expands Research Scope In Tsx Small Cap Index - Kalkine Media
If You Invested $1,000 in Cardiol Therapeu (CRDL) - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Shares Down 1.5%Time to Sell? - MarketBeat
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
Cizzle Brands Corporation Releases Fiscal Q2 2026 Results - Investing News Network
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - MSN
(CRDL) Trading Advice (CRDL:CA) - Stock Traders Daily
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
(CRDL) Optimized Trading Opportunities (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference - MarketBeat
(CRDL) Stock Evaluation Report (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics (CRDL) Stock Analysis Report | Financials & Insights - Benzinga Japan
CRDL: Pivotal phase 3 data for CardiolRx in pericarditis expected late 2024, supporting broad expansion - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Shares Down 1%What's Next? - MarketBeat
(CRDL) Investment Performance Report (CRDL:CA)Stock Traders Daily Canada - Stock Traders Daily
Immix Biopharma to Participate in Upcoming Investor Conferences - Investing News Network
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - The Globe and Mail
Aug Highlights: Should you avoid Cardiol Therapeutics Inc stock right nowPortfolio Performance Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
(CRDL) Market Insights and Trading Signals (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics (TSE:CRDL) Trading Down 4.8%Time to Sell? - MarketBeat
Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) outlines heart programs at TD Cowen - Stock Titan
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference - TMX Newsfile
Heart disease-focused Cardiol to present at TD Cowen conference - Stock Titan
Objective long/short (CRDL) Report (CRDL:CA) - Stock Traders Daily
argenx to Present at TD Cowen 46th Annual Healthcare Conference - Investing News Network
Should I trade or invest in Cardiol Therapeutics Inc.Market Activity Summary & High Conviction Trade Alerts - mfd.ru
CRDLCardiol Therapeu Latest Stock News & Market Updates - Stock Titan
(CRDL) Trading Performance and Risk Management (CRDL:CA)Stock Traders Daily Canada - Stock Traders Daily
Is Cardiol Therapeutics Inc. (CT9) stock a contrarian opportunityWeekly Trade Summary & Long-Term Safe Investment Ideas - mfd.ru
Moderna to Present at Upcoming Conferences in March 2026 - Investing News Network
Learn to Evaluate (CRDL) using the Charts (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5M bought-deal private placement - MSN
Trend Report: Is Cardiol Therapeutics Inc a cyclical or defensive stockExit Point & Reliable Price Breakout Signals - baoquankhu1.vn
(CRDL) Trading Signals (CRDL:CA) - Stock Traders Daily
Moderna to Report Fourth Quarter 2025 Financial Results on Friday, February 13, 2026 - Investing News Network
Aug Drivers: Is Cardiol Therapeutics Inc stock risky to hold nowRecession Risk & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Why Cardiol Therapeutics Inc. stock remains resilientWeekly Investment Summary & AI Driven Stock Price Forecasts - mfd.ru
Is Cardiol Therapeutics Inc. a momentum stockWeekly Profit Report & Safe Capital Growth Plans - mfd.ru
(CRDL) Financial Trading Report (CRDL:CA) - Stock Traders Daily
Published on: 2026-02-16 14:51:25 - baoquankhu1.vn
Can Cardiol Therapeutics Inc generate free cash flow2025 Price Action Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and Centene (CNC) - The Globe and Mail
Cardiol Therapeutics publishes phase II myocarditis study results By Investing.com - Investing.com Nigeria
CRDL Stock Rating Reiterated at 'Buy' by HC Wainwright & Co. | C - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Receives "Buy" Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics publishes phase II myocarditis study results - Investing.com
Cardiol Therapeutics’ ARCHER Phase II Myocarditis Data Published in ESC Heart Failure - TipRanks
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure - Investing News Network
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):